SE406085B - Analogiforfarande for framstellning av 2-homopiperazino-4-amino-6,7-dimetoxikinazoliner - Google Patents

Analogiforfarande for framstellning av 2-homopiperazino-4-amino-6,7-dimetoxikinazoliner

Info

Publication number
SE406085B
SE406085B SE7314678A SE7314678A SE406085B SE 406085 B SE406085 B SE 406085B SE 7314678 A SE7314678 A SE 7314678A SE 7314678 A SE7314678 A SE 7314678A SE 406085 B SE406085 B SE 406085B
Authority
SE
Sweden
Prior art keywords
compound
amino
group
compounds
homopiperazino
Prior art date
Application number
SE7314678A
Other languages
English (en)
Swedish (sv)
Inventor
T Takahashi
H Sugimoto
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of SE406085B publication Critical patent/SE406085B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE7314678A 1972-10-30 1973-10-29 Analogiforfarande for framstellning av 2-homopiperazino-4-amino-6,7-dimetoxikinazoliner SE406085B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10787972A JPS536156B2 (hu) 1972-10-30 1972-10-30
JP47107880A JPS4966691A (hu) 1972-10-30 1972-10-30

Publications (1)

Publication Number Publication Date
SE406085B true SE406085B (sv) 1979-01-22

Family

ID=26447850

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7314678A SE406085B (sv) 1972-10-30 1973-10-29 Analogiforfarande for framstellning av 2-homopiperazino-4-amino-6,7-dimetoxikinazoliner

Country Status (9)

Country Link
US (1) US3920636A (hu)
JP (2) JPS4966691A (hu)
BE (1) BE806626A (hu)
DE (1) DE2354389C2 (hu)
ES (1) ES420046A1 (hu)
FR (1) FR2204424B1 (hu)
GB (1) GB1398455A (hu)
NL (1) NL178076C (hu)
SE (1) SE406085B (hu)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044135A (en) * 1975-10-14 1977-08-23 Abbott Laboratories Antihypertensive agents
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
SE435380B (sv) * 1976-06-15 1984-09-24 Pfizer Forfarande for framstellning av kinazolinforeningar
US4171363A (en) * 1977-02-22 1979-10-16 Bristol-Myers Company 1,2,3-Thiadiazole process
US4101548A (en) * 1977-02-22 1978-07-18 Bristol-Myers Company 1,2,3-Thiadiazole amides
US4098788A (en) * 1977-06-20 1978-07-04 Bristol-Myers Company Process for preparing quinazolines
US4197301A (en) * 1978-10-16 1980-04-08 Allergan Pharmaceuticals, Inc. Topical ophthalmic use of Prazosin
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
JPS56103177A (en) * 1980-01-21 1981-08-18 Eisai Co Ltd Production of 2- n4-n-butyroyl-homopiperazino -4-amino-6,7- dimethoxy-quinazoline hydrochloride
JPS56113770A (en) * 1980-02-13 1981-09-07 Sankyo Co Ltd Novel quinazoline derivative and its preparation
GB2068961B (en) * 1980-02-13 1983-11-30 Sankyo Co Quinazoline derivatives
US4377581A (en) * 1980-03-03 1983-03-22 Pfizer Inc. Chloro- and alkoxy-substituted-2,4-diaminoquinazolines
US4351940A (en) * 1980-03-03 1982-09-28 Pfizer Inc. Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
JPS57116052A (en) * 1981-01-13 1982-07-19 Sankyo Co Ltd Quinazoline derivative and its preparation
JPH0647540B2 (ja) * 1985-07-16 1994-06-22 エーザイ株式会社 虚血性心疾患・不整脈治療・予防剤
GB8910722D0 (en) * 1989-05-10 1989-06-28 Smithkline Beckman Intercredit Compounds
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
DE69842058D1 (de) * 1997-10-27 2011-01-27 Neurosearch As Heteroaryl Diazacycloalkane als cholinergische Ligande für Nikotin-Acetylcholin-Rezeptoren
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
AU758802B2 (en) 1998-09-30 2003-03-27 Takeda Pharmaceutical Company Limited Drugs for improving vesical excretory strength
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
TWI290470B (en) 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CA2481385A1 (en) * 2002-04-12 2003-10-23 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
EP1496878A4 (en) * 2002-04-12 2007-12-26 Celgene Corp TECHNIQUES FOR IDENTIFYING ANGIOGENESIS MODULATORS, COMPOUNDS DISCOVERED BY THESE TECHNIQUES AND TREATMENT TECHNIQUES USING THESE COMPOUNDS
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−２−δリガンド
AU2005269974A1 (en) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-Met activity for the treatment of cancer
US20070213319A1 (en) * 2006-01-11 2007-09-13 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
US8685961B2 (en) * 2006-03-29 2014-04-01 Merck Sharp & Dohme Corp. Diazepan orexin receptor antagonists
UA100974C2 (ru) * 2006-12-01 2013-02-25 Мерк Шарп Энд Доме Корп. Соединения замещенных диазепанов как антагонисты орексиновых рецепторов
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
US7964613B2 (en) 2007-02-28 2011-06-21 Asahi Kasei Pharma Corporation Sulfonamide compound
CA2718412A1 (en) * 2008-03-24 2009-10-01 Celgene Corporation Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US20110014121A1 (en) * 2008-11-04 2011-01-20 Chemocentryx, Inc. Modulators of cxcr7
US8853202B2 (en) * 2008-11-04 2014-10-07 Chemocentryx, Inc. Modulators of CXCR7
CA2742515C (en) * 2008-11-04 2017-07-11 Chemocentryx, Inc. 1,4-diazepane modulators of cxcr7
ES2681593T3 (es) 2012-11-29 2018-09-14 Chemocentryx, Inc. Antagonistas de CXCR7
US9732077B2 (en) 2013-12-18 2017-08-15 Merck Sharp & Dohme Corp. Diazepane orexin receptor antagonists
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
US11464786B2 (en) 2018-12-12 2022-10-11 Chemocentryx, Inc. CXCR7 inhibitors for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3574212A (en) * 1968-02-02 1971-04-06 Pfizer Quinazolinylureas
US3635979A (en) * 1969-09-29 1972-01-18 Pfizer Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines
US3669968A (en) * 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
CH541568A (de) * 1970-12-07 1973-10-31 Ciba Geigy Ag Verfahren zur Herstellung von neuen Imidazolidinonderivaten

Also Published As

Publication number Publication date
BE806626A (fr) 1974-02-15
JPS536156B2 (hu) 1978-03-04
JPS4966690A (hu) 1974-06-27
JPS4966691A (hu) 1974-06-27
FR2204424A1 (hu) 1974-05-24
AU6196973A (en) 1975-05-01
DE2354389C2 (de) 1982-07-15
GB1398455A (en) 1975-06-25
FR2204424B1 (hu) 1977-01-28
NL178076C (nl) 1986-01-16
DE2354389A1 (de) 1974-05-09
NL7314914A (hu) 1974-05-02
US3920636A (en) 1975-11-18
ES420046A1 (es) 1976-02-16

Similar Documents

Publication Publication Date Title
SE406085B (sv) Analogiforfarande for framstellning av 2-homopiperazino-4-amino-6,7-dimetoxikinazoliner
RU2024521C1 (ru) Производные дифенилметилимидазола или их фармацевтически приемлемые соли
PL150240B1 (en) The method of manufacture of new derivatives of benzimidazole
US5541209A (en) Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
JP7439018B2 (ja) 置換アリールエーテル系化合物、その調製方法、医薬組成物およびその応用
HU199425B (en) Process for producing alpha-alkyl-/4-amino-3-quinolinyl/-methanols and 1-square brackets open 4-/aralkylamino/-3-quinolinyl square brackets closed -alkanones, as well as pharmaceutical compositions comprising such compounds as active ingredient
WO1999000381A1 (en) Bis-indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them
AU2017238918B2 (en) Novel crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N- methylmethanamine salt
BRPI0619968A2 (pt) compostos e métodos para inibir a interação de proteìnas bcl com parceiros de ligação
ZA200506797B (en) Water-soluble thalidomine derivatives
KR20100083195A (ko) 신규한 디아제니움디올레이트 유도체, 이들의 제조 방법 및 상기 화합물을 포함하는 약제 조성물
HU206181B (en) Process for producing pharmaceutical compositions comprising optically pure r-(+)-niguldipin and its derivatives and suitable for treating tumoros diseases
DE1913199B2 (de) Mannichbasen aus alpha-Tetralon bzw. dessen Derivaten und Arylalkylaminen und deren Salze
NZ242932A (en) 2-amino-5-cyano-4-quinolinyl-1,4-dihydropyridine derivatives and pharmaceutical compositions
JPS5840552B2 (ja) １，４− ベンゾジオキサンノ アミンユウドウタイノセイホウ
JPS6256474A (ja) ジヒドロピリジン−２−ヒドロキシアミン類
US3941788A (en) Benzimidazole derivatives
US5418235A (en) Aminoalkyl-substituted 5-mercaptothiazoles, the preparation and use thereof
JPH11209284A (ja) 骨形成促進剤
PL89701B1 (hu)
RU2275369C2 (ru) Модуляторы натриевых каналов, являющиеся производными 2-пиперидилимидазолов
HU225956B1 (en) 1-ar(alk)yl-imidazolin-2-ones containing a disubstituted amine radical in the 4th position, having an anti-convulsive effect and process for their production, their use and pharmaceuticals containing the same
FI60863B (fi) Foerfarande foer framstaellning av nya bentshydryloxialkylaminderivat med foerlaengd antihistamineffekt
KR20190126525A (ko) 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물
US5424312A (en) Aminoalkyl-substituted 2-amino-1,3,4-thiadiazoles, the preparation and use thereof